Organovo Holdings logo
Organovo Holdings ONVO
report update icon

Annual report 2026
added 07-14-2026

Organovo Holdings Balance Sheet 2026-2008 | ONVO

Brief overview of Organovo Holdings's balance sheet structure

The comparison uses five available annual reports from the 2019–2025 interval.

Assets finished at $14.7 million versus $40.6 million initially, losing -63.9%. The balance sheet contracted.

Liabilities expanded faster than the asset base, -3.9% versus -63.9%. Debt-service capacity deserves attention.

Internal capital represents 71.6% of the balance sheet, previously 89.4%. This is a strong capital position.

The balance sheet holds more cash than interest-bearing debt; net debt is -$10.4 million, indicating minimal leverage.

Cash equals 77.2% of the balance sheet, compared with 89.8% five periods ago. This is the readily available cushion.

Retained earnings are negative at -$342.2 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.

Balance sheet takeaway

Organovo Holdings has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.

Annual Balance Sheet Organovo Holdings

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Net Debt

- -10.4 M -1.51 M -13.5 M -26.5 M - -27.4 M -36.5 M -43.7 M -62.8 M -62.1 M -50.1 M -48.2 M -15.6 M -14.8 M -1.78 K - - -

Long Term Debt

- 421 K 888 K 1.31 M 1.7 M - - - - - - - - 20 K - - - - -

Long Term Debt Current

447 K 521 K 506 K 492 K 479 K - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - 588 K 583 K 807 K 905 K 32 K 9 K 30 K 17 K - - - -

Total Current Liabilities

2.78 M 3.74 M 1.86 M 3.67 M 1.38 M 721 K 1.81 M 3.74 M 4.66 M 6.01 M 4.49 M 4.76 M 1.89 M 8.38 M 22 M 1.98 M - - -

Total Liabilities

8.48 M 4.16 M 2.75 M 4.98 M 3.09 M - 1.81 M 4.32 M 5.24 M 6.82 M 5.4 M 4.79 M 1.9 M 8.41 M 22.1 M 10.7 K - - -

Deferred Revenue

- - - - - - - 525 K 668 K 582 K 1.11 M 227 K 13 K - - - - - -

Retained Earnings

-356 M -342 M -340 M -325 M -308 M -296 M -279 M -261 M -234 M -199 M -161 M -122 M -92.2 M -66.4 M -50.2 M -186 K - - -

Total Assets

7.39 M 14.6 M 6.35 M 20.3 M 33.3 M 39.9 M 28.4 M 40.6 M 49.8 M 69.2 M 67.6 M 53.5 M 50.2 M 17.4 M 16.7 M 4.28 K - - -

Cash and Cash Equivalents

5.02 M 11.3 M 2.9 M 15.3 M 28.7 M 37.4 M 27.4 M 36.5 M 43.7 M 62.8 M 62.1 M 50.1 M 48.2 M 15.6 M 14.8 M 340 K 285 K 141 K -

Book Value

-1.1 M 10.5 M 3.6 M 15.3 M 30.2 M 39.9 M 26.6 M 36.3 M 44.6 M 62.4 M 62.2 M 48.7 M 48.3 M 8.97 M -5.3 M -6.42 K - - -

Total Shareholders Equity

-1.1 M 10.5 M 364 K 15.3 M 30.2 M 39.2 M 26.6 M 36.3 M 44.6 M 62.4 M 62.2 M 48.7 M 48.3 M 8.97 M -5.3 M -1.84 M -2.3 M -966 K -96 K

All numbers in USD currency

Quarterly Balance Sheet Organovo Holdings

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

44 K 172 K 298 K 421 K 543 K 660 K 775 K 888 K 999 K 1.1 M 1.21 M 1.31 M 1.41 M 1.52 M 1.61 M 1.7 M 1.8 M - - - - - - - - 3.58 M 3.77 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

2.52 M 2.62 M 2.44 M 4.16 M 3.48 M 3.07 M 2.81 M 2.75 M 2.7 M 2.7 M 2.98 M 4.98 M 2.79 M 2.9 M 2.89 M 3.09 M 3.8 M 721 K - 721 K - - - 1.81 M 2.36 M 6.7 M 7.31 M 4.32 M 4.01 M 3.76 M 3.74 M 5.24 M 4.95 M 4.85 M 4.44 M 6.82 M 5.23 M 5.05 M 4 M 5.4 M 5.5 M 5.52 M 5.24 M 4.79 M 3.76 M 3.11 M 3.09 M 1.9 M 2.91 M 2.96 M 7.6 M 8.41 M 22.1 M 34.5 M 81.5 M 48.6 M 3.24 M 3.24 M 3.24 M 3.24 M

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - 532 K 525 K 580 K 619 K 628 K 668 K 857 K 654 K 854 K 582 K 620 K 479 K 791 K 1.11 M 1.44 M 1.4 M 1.43 M 227 K 241 K 140 K 144 K 13 K 15 K 75 K 28 K 53 K - 75 K 223 K 269 K 153 K 152 K 152 K 152 K

Retained Earnings

-350 M -348 M -345 M -342 M -349 M -346 M -343 M -340 M -337 M -333 M -329 M -325 M -318 M -314 M -311 M -308 M -306 M -302 M -299 M -296 M -294 M -291 M -282 M -279 M -277 M -273 M -267 M -261 M -254 M -247 M -242 M -234 M -227 M -219 M -209 M -199 M -189 M -179 M -170 M -161 M -152 M -142 M -131 M -122 M - - - - - - - - - - - - - - - -

Total Assets

6.96 M 9.69 M 12 M 14.6 M 3.84 M 6.75 M 9.47 M 6.35 M 8.88 M 11.2 M 14.8 M 20.3 M 25.1 M 27.9 M 30.5 M 33.3 M 35.1 M 35.9 M 38.3 M 39.9 M 21.6 M 20.6 M 25.6 M 28.4 M 31.3 M 37.8 M 43.5 M 40.6 M 39.7 M 42.6 M 45.1 M 49.8 M 53.6 M 56.9 M 61.7 M 69.2 M 76.1 M 57.5 M 58.8 M 67.6 M 74.5 M 81.7 M 90.6 M 53.5 M 52.1 M 56.5 M 46.9 M 50.2 M 51.6 M 54.9 M 14.5 M 17.4 M 16.7 M 9.04 M 9.71 M 11.2 M 1.41 M 1.41 M 1.41 M 1.41 M

Cash and Cash Equivalents

4.29 M 6.68 M 9.06 M 11.3 M 1.16 M 3.17 M 6.19 M 2.9 M 5.3 M 7.62 M 10.8 M 15.3 M 20.2 M 13.3 M 15.6 M 28.7 M 30.3 M 33.8 M 36 M 37.4 M 18.8 M 18.8 M 17.7 M 24.8 M 30.5 M 30.5 M 30.4 M 35.5 M 35.2 M 35.2 M 37.4 M 43.7 M 47.3 M 50.7 M 55 M 62.8 M 70 M 51.7 M 53.5 M 62.1 M 70 M 76.9 M 86 M 50.1 M 50 M 54.4 M 44.9 M 48.2 M 49.8 M 53.4 M 12.8 M 15.6 M 14.8 M 14.8 M 8.47 M 10.4 M 340 K 340 K 340 K 340 K

Book Value

4.44 M 7.06 M 9.54 M 10.5 M 364 K 3.68 M 6.66 M 3.6 M 6.18 M 8.46 M 11.8 M 15.3 M 22.3 M 25 M 27.7 M 30.2 M 31.3 M 35.2 M 38.3 M 39.2 M 21.6 M 20.6 M 25.6 M 26.6 M 29 M 31.1 M 36.1 M 36.3 M 35.7 M 38.9 M 41.4 M 44.6 M 48.6 M 52.1 M 57.3 M 62.4 M 70.9 M 52.5 M 54.8 M 62.2 M 69 M 76.2 M 85.3 M 48.7 M 48.3 M 53.4 M 43.8 M 48.3 M 48.7 M 51.9 M 6.91 M 8.97 M -5.3 M -25.4 M -71.8 M -37.4 M -1.84 M -1.83 M -1.83 M -1.83 M

Total Shareholders Equity

4.44 M 7.06 M 9.54 M 10.5 M 364 K 3.68 M 6.66 M 3.6 M 6.18 M 8.46 M 11.8 M 15.3 M 22.3 M 25 M 27.7 M 30.2 M 31.3 M 34.2 M 37.3 M 39.2 M 20.8 M 20 M 24.8 M 26.6 M 29 M 31.1 M 36.1 M 36.3 M 35.7 M 38.9 M 41.4 M 44.6 M 48.6 M 52.1 M 57.3 M 62.4 M 70.9 M 52.5 M 54.8 M 62.2 M 69 M 76.2 M 85.3 M 48.7 M 48.3 M 53.4 M 43.8 M 48.3 M 48.7 M 51.9 M 6.91 M 8.97 M -5.3 M -5.3 M -5.3 M -5.3 M -1.84 M -1.83 M -1.83 M -1.83 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Organovo Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Diagnostics research

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
$ 11.73 -1.26 % $ 1.05 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 16.5 -1.02 % $ 695 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.22 -0.31 % $ 26.1 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Exagen Exagen
XGN
$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 178.18 -1.14 % $ 14 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA